Workflow
Arcus Biosciences, Inc. (RCUS) Reports Q1 Loss, Lags Revenue Estimates
RCUSArcus Biosciences(RCUS) ZACKS·2025-05-06 23:10

Company Performance - Arcus Biosciences reported a quarterly loss of 1.14pershare,whichwasworsethantheZacksConsensusEstimateofalossof1.14 per share, which was worse than the Zacks Consensus Estimate of a loss of 1.02, and compared to a loss of 0.05pershareayearago,indicatingasignificantdeclineinperformance[1]−Thecompanypostedrevenuesof0.05 per share a year ago, indicating a significant decline in performance [1] - The company posted revenues of 28 million for the quarter ended March 2025, missing the Zacks Consensus Estimate by 14.24%, and a sharp decline from year-ago revenues of 145million[2]−Overthelastfourquarters,ArcusBioscienceshassurpassedconsensusEPSestimatestwotimesandtoppedconsensusrevenueestimatesthreetimes[2]StockPerformance−ArcusBiosciencesshareshavelostabout40145 million [2] - Over the last four quarters, Arcus Biosciences has surpassed consensus EPS estimates two times and topped consensus revenue estimates three times [2] Stock Performance - Arcus Biosciences shares have lost about 40% since the beginning of the year, significantly underperforming the S&P 500, which declined by only 3.9% [3] - The current consensus EPS estimate for the coming quarter is -1.08 on revenues of 30.7million,andforthecurrentfiscalyear,itis−30.7 million, and for the current fiscal year, it is -4.13 on revenues of $123.83 million [7] Industry Outlook - The Medical - Biomedical and Genetics industry, to which Arcus Biosciences belongs, is currently ranked in the top 31% of over 250 Zacks industries, suggesting a favorable industry outlook [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact the stock's performance [5]